The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

IMRX FINANCIAL STATEMENTS

Immuneering Corp — balance sheet, income statement and cash flow trends

IMRXImmuneering Corp

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-100 M0100 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue361 K $Gross Profit-698.9 K $ · -194%Operating Income-19 B $ · -5276203%Pre-tax Income-17.3 B $ · -4795692%Net Income to Owners-57.3 M $ · -15868%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue361 K $-50.3%
Gross Profit-698.9 K $—
Operating Income-19 B $—
EBITDA-63.4 M $—
Net Income to Owners-57.3 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0100 B200 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets202.1 M
  • Equity190.7 M $94%
  • Current Liabilities8.1 M $4%
  • Long-term Liabilities3.2 M $2%

Key Figures

YoY change
Total Assets202.1 M $+404.4%
Total Liabilities11.3 M $+1.8%
Total Equity190.7 M $+559.2%
Cash & ST Investments149.9 M $+468.8%
Total Debt3.6 M $-9.2%
Net Debt-37.7 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-30 B-20 B-10 B0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-75 B-50 B-25 B0-35 B $Operating-52.7 B $Investing418.2 M $Financing-87.2 B $Net Change

Key Figures

YoY change
Operating Cash Flow-35 B $—
Capital Expenditures107.4 M $+418,136.3%
Free Cash Flow-35.1 B $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on IMRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.